<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/223154-combination-of-sibutramine-with-cannabinoid-1-receptor-antagonist by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 06:40:45 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 223154:COMBINATION OF SIBUTRAMINE WITH CANNABINOID 1 RECEPTOR ANTAGONIST</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">COMBINATION OF SIBUTRAMINE WITH CANNABINOID 1 RECEPTOR ANTAGONIST</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>PATENT COMBINATION OF A CBl RECEPTOR ANTAGONIST AND OF SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF OBESITY AVENTIS PHARMA S.A. ABSTRACT The present invention relates to the combination of a CBl receptor antagonist and of sibutramine, to the pharmaceutical compositions comprising them and to their use in the treatment of obesity.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td> <br><br><br>
The present invention relates to the combination of a CBl receptor antagonist and of sibutramine, to the pharmaceutical compositions comprising them and to their use in the treatment of obesity.<br>
CBl receptor antagonists are known for their effect on food intake and their use as anorexigenic (G. Colombo et al., Life Sciences, 63 (8), 113-117 (1998); J. Siamand et al., Behavioural Pharmacol., 9, 179-181 (1998)).<br>
Sibutramine (BTS 54524; N-(1-[1-(4-chloro-phenyl)cyclobutyl]-3-methylbutyl}-N, N-dimethylamine; Meridia", Reductil') , its hydrate and its pharma-ceutically acceptable salts and in particular its hydrochloride reduces food intake and is of use in the treatment of obesity (WO 90/061110; D.H. Ryan et al.. Obesity Research, 3 (4), 553 (1995); H.C. Jackson et al., British Journal of Pharmacology, 121, 1758 (1997); G. Fanghanel et al,. Inter. J. Obes., 24 (2), 144 (2000); G.A. Bray et al., Obes. Res., 7 (2), 189 (1999)).<br>
It has now been found that the combination of sibutramine, its hydrate and its pharmaceutically acceptable salts and of a CBl receptor antagonist exhibits a synergistic effect in reducing food consumption and is thus of use in the treatment of obesity.<br>
The combination can also comprise several CBl receptor antagonists.<br>
Use may in particular be made, among CBl [lacuna] antagonists, of the azetidine derivatives<br><br>
disclosed in WO 00/15609, WO 01/64633 and WO 01/64634 of formula:<br><br>
Ra represents either an aromatic chosen from phenyl, naphthyl or indenyl, these aromatics being unsubstituted or substituted by one or more halogen, alkyl, alkoxy, -CO-alk, hydroxyl, -COOR5, formyl, trifluoromethyl, trifluoromethylsulfanyl, trifluoromethoxy, nitro, -NReR, -CO-NH-NR6R7, -N(alk)C00R8, cyano, -CONHR9, -CO-NR16R17, alkylsulf anyl,' hydroxyalkyl, -0-alk-NR12R13 or alkylthioalkyl, or a heteroaromatic chosen from the benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, 2,3-dihydrobenzofuryl, 2,3-dihydrobenzothienyl, indolinyl, indolyl, isochromanyl, isoquinolyl, pyridyl, quinolyl, 1,2,3,4-tetrahydroisoquinolyl, 1,2,3,4-tetrahydroquinolyl, thiazolyl or thienyl rings, it being possible for these heteroaromatics to be<br><br>
unsubstituted or substituted by a halogen, alkyl, alkoxy, -COOR5, trifluoromethy],<br>
trifluoromethylsulfanyl, trifluoromethoxy, nitre, -NR6R7, -CO-NH-NRgRv, cyano, -CONHR9, alkylsulf anyl, hydroxyalkyl or alkylthioalkyl,<br>
R3 and R4, which are identical or different, represent either an aromatic chosen from phenyl, naphthyl or indenyl, these aromatics being unsubstituted or substituted by one or more halogen, alkyl, alkoxy,-formyl, hydroxyl, trifluoromethyl, trifluoromethoxy, -CO-alk, cyano, -COOR5, -CONRioRn, -CO-NH-NRgRv, alkylsulfanyl, hydroxyalkyl, -alk-NReR or alkylthioalkyl, or a heteroaromatic chosen from the benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, 2,3-dihydrobenzofuryl, 2,3-dihydro-benzothienyl, furyl, isochromanyl, isoquinolyl, pyrrolyl, quinolyl, 1,2,3, 4-tetrahydroisoquinolyl, thiazolyl or thienyl rings, it being possible for these heteroaromatics to be unsubstituted or substituted by a halogen, alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, -COOR5, -CO-NH-NR6R7, -CONRioRu. -alk-NReR, alkylsulfanyl, hydroxyalkyl or alkylthioalkyl,<br>
R5 is an alkyl radical or a phenyl radical optionally substituted by one or more halogen atoms.<br>
Re and R7, which are identical or different, represent a hydrogen atom or an alkyl, -COOalk, cycloalkyl, alkylcycloalkyl, -alk-0-alk or hydroxyalkyl radical or else Re and R form, together with the nitrogen atom to which they are attached, a saturated or unsaturated and mono- or bicyclic heterocycle having 3 to 10 ring . members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being<br><br>
substituted by one or more alkyl, -COalk, -COOalk,. -CO-NHalk, -CS-NHalk, -CO-alk-NRiRis, oxo, hydroxyalkyl, -alk-0-alk or -CO-NH2 radicals,<br>
 Ra represents an alkyl radical,<br>
Rg represents a hydrogen atom or a radical of the type alkyl or alkyl substituted by dialkylamino, phenyl, cycloalkyl (optionally substituted by -COOalk) or a ' saturated or unsaturated and mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising one or more heteroatoms chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl radicals,<br>
R10 and R11, which are identical or different, represent a hydrogen atom or an alkyl radical or else R10 and Rn form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by an alkyl radical,<br>
R12 and R13, which are identical or different, represent a hydrogen atom or an alkyl or cycloalkyl radical or else R12 and R13 form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic -heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by an alkyl, -COalk, -COOalk, -CO-NHalk, -CS-NHalk or -CO-alk-NRi4Ri5 radical or a saturated mono- or bicyclic heterocycle having 3 to 10 ring members and comprising  a heteroatom chosen from oxygen, sulfur and nitrogen.<br><br>
R14 and R15, which are identical or different, represent a hydrogen atom or an alkyl or -COOalk radical,<br>
R16 and Ri7 form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen,<br>
R' represents a hydrogen atom or a -CO-alk radical,<br>
or R represents a CHRia radical and<br>
R18 represents an -NHCOR19 or -N (R20)-Y-R21 radical,<br>
Y is CO or SO2,<br>
R4 and R3, which are identical or different, represent either an aromatic chosen from phenyl, naphthyl and indenyl, these aromatics being unsubstituted or substituted by one or more halogen, alkyl, alkoxy, formyl, hydroxyl, trifluoromethyl, trifluoromethoxy, -CO-alk, cyano, -COOH, -COOalk, -CONR22R23/ -CO-NH-NR24R25, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, hydroxyalkyl or -alk-NH22R23r or a heteroaromatic chosen from the benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, 2,3-dihydrobenzofuryl, 2,3-dihydrobenzothienyl, pyrimidinyl, furyl, imidazolyl, isochromanyl, isoquinolyl, pyrrolyl, pyridyl, quinolyl, 1,2,3,4-tetrahydroisoquinolyl, thiazolyl and thienyl rings, it being possible for these heteroaromatics to be unsubstituted or substituted by a halogen, alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, -COOH, -COOalk, -CO-NH-NR24R25, -CONR22R23, -alk-<br><br>
NR24R25/ alkylsulfanyl, alkylsulfinyi, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl or hydroxyalkyl,<br>
Ri9 represents an -alk-S02-R26 radical, an -alk-S02-CH=CH-R26 radical, a Heti radical substituted by -SO2-R26 or a phenyl radical substituted by -SO2-R26 or -alk-SO-R26/<br>
R20 represents a hydrogen atom or an alkyl radical,<br>
R21 represents a phenylalkyl, Heti or Ari radical,<br>
R22 and R23, which are identical or different, represent a hydrogen atom or an alkyl radical or else R22 and R23 form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one o.r more alkyl,<br>
R24 and R25, which are identical or different, represent a hydrogen atom or an alkyl, -COOalk, cycloalkyl, alkylcycloalkyl, -alk-0-alk or hydroxyalkyl radical or else R24 and R25 form, together with the nitrogen atom to which they are attached, a saturated or unsaturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl, -COalk, -COOalk, -CO-NHalk, -CS-NHalk, 0x0, hydroxyalkyl, -alk-0-alk or -CO-NH2,<br>
R26 represents an alkyl, Ari or Heti radical.<br><br>
Ari represents a phenyl, naphthyl or indenyl radical, these radicals optionally being substituted by one or more halogen, alkyl, alkoxy, cyano, -CO-alk, -COOH, -COOalk, -CONR27R28, -CO-NH-NR29R30, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, -alk-NR29R3o, -NR29R30, alkylthioalkyl, formyl, hydroxyl, hydroxyalkyl, Het, -0-alk-NH-cycloalkyl, OCF3, CF3, -NH-CO-alk, -SO2NH2, -NH-COCH3, -NH-COOalk or Het or else on 2 adjacent carbon atoms by dioxymethylene,<br>
Heti represents an unsaturated or saturated mono- or bicyclic heterocycle having 3 to 10 ring members and comprising one or more heteroatoms chosen from oxygen, sulfur and nitrogen which is optionally substituted by one or more alkyl, alkoxy, vinyl, halogen, alkoxycarbonyl, 0x0, hydroxyl, OCF3 or CF3, the nitrogenous heterocycles optionally being in their N-oxidized form,<br>
R27 and R28/ which are identical or different, represent a hydrogen atom or an alkyl radical or else R27 and R28 form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl radicals,<br>
R29 and R30, which are identical or different, represent a hydrogen atom or an alkyl, -COOalk, cycloalkyl, alkylcycloalkyl, -alk-0-alk or hydroxyalkyl radical or else R29 and R30 form, together with the nitrogen atom to which they are attached, a saturated or unsaturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being<br><br>
substituted by one or more alkyl, -COalk, -COOalk, -CO-NHalk, -CS-NHalk, oxo, hydroxyalkyl, -alk-0-alk or -CO-NH2 radicals,<br>
or R represents CHR31 and<br>
R31 represents an -N(R32)R33, -N (R32)-CO-R33 or -N (R32)-SO2R34 radical,<br>
R4 and R3, which are identical or different, represent either an aromatic chosen from phenyl, naphthyl and indenyl, these aromatics being unsubstituted or substituted by one or more halogen, alkyl, alkoxy, formyl, hydroxyl, trifluoromethyl, trifluoromethoxy, -CO-alk, cyano, -COOH, COOalk, -CONR22R23, -CO-NH-NR24R25, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, hydroxyalkyl or -alk-NR7R8/ or a heteroaromatic chosen from the benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, 2,3-dihydrobenzofuryl, 2,3-dihydrobenzothienyl, furyl, imidazolyl, isochromanyl, isoquinolyl, pyrrolyl, pyridyl, pyrimidyl, quinolyl, 1,2,3,4-tetra-hydroisoquinolyl, thiazolyl and thienyl rings, it being possible for these heteroaromatics to be unsubstituted or substituted by a halogen, alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, -COOH, -COOalk, -CO-NH-NR24R25, -CONR22R23, -alk-NR24R25, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl or hydroxyalkyl,<br>
R32 represents a -C (R35) (Rse)-Het2, -Het2, -C (R35) (R36)-Ar2, Ar2, cycloalkyl or norbornyl radical.<br><br>
R33 represents a hydrogen atom or a hydroxyalkyl, -alk-COOalk, -alk-CONR22R23, -alk-NR22R23, alkoxy, Ar2, Het2, -CH2Ar2, -CH2Het2 or alkyl radical, the latter optionally substituted by one or more halogen,<br>
R34 represents a hydroxyalkyl, -alk-COOalk, -alk-CONR22R23, -alk-NR22R23, alkoxy, Ar2, Het2, -CH2Ar2, -CH2Het2 or alkyl radical, the latter optionally substituted by one or more halogen,<br>
R35 represents a hydrogen atom or a hydroxyalkyl, -alk-COOalk, -alk-CONR22R23/ -alk-NR22R23, alkoxyalkyl, Ar2, Het2, -CH2Ar2, -CH2Het2 or alkyl radical, the latte optionally substituted by one or more halogen,<br>
R36 represents a hydrogen atom or a hydroxyalkyl, -alk-COOalk, -alk-CONR22R23, -alk-NR22R23, alkoxyalkyl or alkyl radical, the latter optionally substituted by om or more halogen,<br>
or else R35 and R36 form, together with the carbon atom to which they are attached, a saturated mono- or bicyclic ring having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted b; one or more alkyl,<br>
Ar2 represents a phenyl, naphthyl or indenyl radical, these various radicals optionally being substituted by one or more halogen, alkyl, alkoxy, -CO-alk, cyanq, -COOH, -COOalk, -CONRsiRss, -CO-NH-R39R40, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, -alk-NR39R40A -NR39R40 alkylthioalkyl, formyl, CF3, OCF3, Het, -0-alk-NH-cycloalkyl, SO2NH2, hydroxyl, hydroxyalkyl, -NHCOalk or NHCOOalk or on 2 adjacent carbon atoms by dioxymethylene,<br><br>
Het2 represents an unsaturated or saturated mono- or bicyclic heterocycle having 3 to 10 ring members and comprising one or more heteroatoms chosen from oxygen, sulfur and nitrogen which is optionally substituted by one or more alkyl, alkoxy, halogen, alkoxycarbonyl, oxo or hydroxyl, the nitrogenous heterocycles optionally being in their N-oxidized form,<br>
R37 and R38, which are identical or different, represent a hydrogen atom or an alkyl radical or else R37 and R38 form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl,<br>
R39 and R40, which are identical or different, represent a hydrogen atom or an alkyl radical or else R39 and R40 form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl,<br>
alk represents an alkyl or alkylene radical,<br>
the alkyl and alkylene radicals and portions and the alkoxy radicals and portions have straight or branched chains and comprise 1 to 6 carbon atoms and the cycloalkyl radicals comprise 3 to 10 carbon atoms.<br><br>
the optical isomers of these compounds and their pharmaceutically acceptable salts with an inorganic or organic acid.<br>
The preferred azetidine derivatives are as follows:<br>
l-benzhydryl-3-[(methylsulfonyl)(phenyl)-methylene]azetidine,<br>
l-benzhydryl-3-[(3-methylphenyl)(methylsulfonyl)-methylene]azetidine,<br>
l-benzhydryl-3-[(3-chlorophenyl)(methylsulfonyl)-methylene]azetidine,<br>
l-benzhydryl-3-[(3,5-dichlorophenyl)(methylsulfonyl)-methylene]azetidine,<br>
l-benzhydryl-3-[(2,5-dichlorophenyl)(methylsulfonyl)-methylene]azetidine,<br>
l-benzhydryl-3-[(2,3-dichlorophenyl)(methylsulfonyl)-methylene]azetidine,<br>
l-benzhydryl-3-[(3-fluorophenyl)(methylsulfonyl)-methylene]azetidine,<br>
l-benzhydryl-3-[(3,5-difluorophenyl)(methylsulfonyl)-methylene]azetidine,<br>
l-benzhydryl-3-[(3-bromophenyl)(methylsulfonyl)-methylene]azetidine,<br>
l-benzhydryl-3-[(3-iodophenyl)(methylsulfonyl)-methylene]azetidine,<br>
l-benzhydryl-3-[(methylsulfonyl)(3-trifluoro-methoxyphenyl)methylene]azetidine, l-benzhydryl-3-[(methylsulfonyl)(3-trifluoro-methylphenyl)methylene]azetidine, l-benzhydryl-3-{[3,5-bis(trifluoromethyl)phenyl]-<br>
(methylsulfonyl)methylene}azetidine,<br>
l-benzhydryl-3-[(3,5-dibromophenyl)(methylsulfonyl)-<br>
methylene]azetidine,<br>
l-benzhydryl-3-[(3-methoxycarbonylphenyl)-<br>
(methylsulfonyl)methylene]azetidine.<br><br>
l-benzhydryl-3-[(3-cyanophenyl)(methylsulfonyl)-methylene]azetidine,<br>
l-benzhydryl-3-[(3-carbamoylphenyl)(methylsulfonyl)-methylene]azetidine,<br>
l-benzhydryl-3-[(methylsulfonyl)(naphth-1-yl)(methyl¬sulfonyl) methylene] azetidine,<br>
1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine, 1-[bis(4-methoxyphenyl)methyl]-3-[(3, 5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine, 1-[bis(4-methylphenyl)methyl]-3-[(3, 5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine,<br>
(RS)-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-1-[(4-methoxyphenyl)(phenyl)methyl)]azetidine,<br>
(R)-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-1-[(4-methoxyphenyl)(phenyl)methyl]azetidine,<br>
(S)-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-<br>
1-[(4-methoxyphenyl)(phenyl)methyl]azetidine,<br>
1-[bis(4-trifluoromethoxyphenyl)methyl]-3-[(3,5-di-<br>
fluorophenyl)(methylsulfonyl)methylene]azetidine,<br>
1-[bis(4-trifluoromethylphenyl)methyl]-3-[(3,5-di-<br>
fluorophenyl)(methylsulfonyl)methylene]azetidine,<br>
1-[bis(4-chlorophenyl)methyl]-3-{[3,5-bis(trifluoro-<br>
methyl)pheny1]methyIsulfonylmethylene}azetidine,<br>
(RS)-1-[(4-chlorophenyl)(2,4-dichlorophenyl)methyl]-3-<br>
[(3,5-difluorophenyl)(methylsulfonyl)-methylene]azetidine,<br>
(R)-1-[(4-chlorophenyl)(2,4-dichlorophenyl)methyl]-3-<br>
[(3,5-difluorophenyl)(methylsulfonyl)-methylene]azetidine,<br>
(S)-1-[(4-chlorophenyl)(2,4-dichlorophenyl)methyl]-3-<br>
[(3,5-difluorophenyl)(methylsulfonyl)-methylene]azetidine,<br>
(RS)-l-{(4-chlorophenyl)[4-<br>
(hydroxymethyl)phenyl]methyl}-3-[(3,5-difluoro¬phenyl) (methylsulfonyl)methylene]azetidine,<br><br>
(R)-l-{ (4-chlorophenyl) L4-<br>
(hydroxymethyl)phenyl]methyl}-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine, (S)-l-{ (4-chlorophenyl) [4-<br>
(hydroxymethyl)phenyl]methyl}-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine, (RS)-l-{(4-chlorophenyl)[4-<br>
(pyrrolidylmethyl)phenyl]methyl}-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine, (R)-l-( (4-chlorophenyl) [4-<br>
(pyrrolidylmethyl)phenyl]methyl}-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine, (S)-l-((4-chlorophenyl)[4-<br>
(pyrrolidylmethyl)phenyl]methyl}-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine, l-{(RS)-(4-chlorophenyl)[4-(3,3-dimethylpiperidin-l-ylmethyl)phenyl]methyl}-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine, l-{(R)-(4-chlorophenyl)[4-(3,3-dimethylpiperidin-l-ylmethyl)phenyl]methyl}-3-[(3, 5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine, l-{(S)-(4-chlorophenyl)[4-(3,3-dimethylpiperidin-l-ylmethyl)phenyl]methyl}-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine, l-{(RS)-(4-chlorophenyl)[4-(thiomorpholin-4-ylmethyl)phenyl]methyl}-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine, l-{(R)-(4-chlorophenyl)[4-(thiomorpholin-4-ylmethyl)phenyl]methyl}-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine, l-{(S)-(4-chlorophenyl)[4-(thiomorpholin-4-ylmthyl)phenyl]methyl}-3-[(3, 5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine, l-{(RS)-(4-chlorophenyl)[4-(N-ethyl-N-cyclohexylaminomethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine.<br><br>
l-((R)-(4-chlorophenyl)[4-(N-ethyl-N-cyclohexylaminomethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, l-((S)-(4-chlorophenyl)[4-(N-ethyl-N-cyclohexylaminomethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, l-(((RS)-(4-chlorophenyl)(4-[(4-ethoxycarbonyl-piperazinyl)methyl]phenyl}methyl}}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, l-{((R)-(4-chlorophenyl){4-[(4-ethoxycarbonyl-piperazinyl)methyl]phenyl}methyl}}-3-[(3,5-dif luorophenyl) (methylsulfonyl)methylene]azetidine, l-{{(S)-(4-chlorophenyl){4-[(4-ethoxycarbonyl-piperazinyl)methyl]phenyl}methyl}}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, l-((RS)-(4-chlorophenyl)[4-(N-cyclopropyl-N-propylaminomethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, l-((R)-(4-chlorophenyl)[4-(N-cyclopropyl-N-propylaminomethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, l-((S)-(4-chlorophenyl)[4-(N-cyclopropyl-N-propylaminomethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, l-{(RS)-(4-chlorophenyl)[4-(diisopropylamino-methyl)phenyl]methyl}-3-[(3, 5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, l-{(R)-(4-chlorophenyl)[4-(diisopropylaminomethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl¬sulfonyl) methylene] azetidine,<br>
l-{(S)-(4-chlorophenyl)[4-(diisopropylaminomethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)-methylene]azetidine,<br>
l-({(RS)-(4-chlorophenyl){4-[bis(2-methoxyethyl)-aminomethyl]phenyl}methyl}}-3-[(3, 5-difluorophenyl)-(methylsulfonyl)methylene]azetidine.<br><br>
l-{((R)-(4-chlorophenyl){4-[bis(2-methoxyethyl)-aminomethyl]phenyl}methyl}}-3-[(3, 5-difluoropbenyl)-(methylsulfonyl)methylene]azetidine, l-{{(S)-(4-chlorophenyl)(4-[bis(2-methoxyethyl)-aminomethyl]phenyl}methyl}}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, l-{(RS)-(4-chlorophenyl)[4-[di-n-<br>
propylaminomethyl)phenyl]methyl}-3-[(3,5-difluoro¬phenyl) (methylsulfonyl)methylene]azetidine, l-{(R)-(4-chlorophenyl)[4-(di-n-propylaminomethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)-methylene]azetidine,<br>
l-{(S)-(4-chlorophenyl)[4-(di-n-propylaminomethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl¬sulfonyl) methylene] azetidine,<br>
l-((RS)-(4-chlorophenyl)[4-(piperidin-1-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl¬sulfonyl) methylene] azetidine,<br>
l-{(R)-(4-chlorophenyl)[4-(piperidin-1-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl¬sulfonyl) methylene]azetidine,<br>
l-{(S)-(4-chlorophenyl)[4-(piperidin-1-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl¬sulfonyl) methylene] azetidine,<br>
l-{(RS)-(4-chlorophenyl)[4-(4-methylpiperazin-l-ylmethyl)phenyl]methyl}-3-[(3, 5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, l-{(R)-(4-chlorophenyl)[4-(4-methylpiperazin-l-ylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, l-{(S)-(4-chlorophenyl)[4-(4-methylpiperazin-l-ylmethyl)phenyl]methyl}-3-[(3, 5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, l-{(RS)-(4-chlorophenyl)[4-(morpholin-4-ylmethyl)phenyl]methyl}-3-[(3, 5-difluorophenyl)-(methylsulfonyl)methylene]azetidine.<br><br>
(R)-l-{(4-chlorophenyl)[4-(N,N-dimethylcarbamoyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methyIsulfonyl)methylene]azetidine, (S)-l-( (4-chlorophenyl) [4-(N,N-dimethylcarbamoyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, (RS)-l-((4-chlorophenyl)[4-(N-ethylcarbamoyl)phenyl]methyl)}-3- [ (3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, (R)-l-{(4-chlorophenyl)[4-(N-ethylcarbamoyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, (S)-l-( (4-chlorophenyl) [4-(N-ethylcarbamoyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, (RS)-1-[(4-carbamoylphenyl)(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-azetidine,<br>
(R)-1-[(4-carbamoylphenyl)(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-azetidine,<br>
(S)-1-[(4-carbamoylphenyl)(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-azetidine,<br>
1- [bis(4-chlorophenyl)methyl]-3-[(3,5-dichloro-phenyl)(methylsulfonyl)methylene]azetidine, l-benzhydryl-3-[(3-methylsulfanylphenyl)(methyl¬sulfonyl) methylene] azetidine,<br>
l-benzhydryl-3-[(3-methylsulfanylmethyl)phenyl)]-(methylsulfonyl)methylene]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(3-cyanophenyl)-(methyIsulfonyl)methylene]azetidine,<br>
1-[bis(4-chlorophenyl)methyl]-3-[(3-carbamoylphenyl)• (methyIsulfonyl)methylene]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(3-methoxyphenyl)-(methyIsulfonyl)methylene]azetidine.<br><br>
l-((R)-(4-chlorophenyl)[4-(morpholin-4-ylmethyl)-<br>
phenyl]methyl}-3-[(3,5-difJuorophenyl)-<br>
(methylsulfonyl)methylene]azetidine,<br>
l-{(S)-(4-chlorophenyl)[4-(morpholin-4-ylmethyl)-<br>
phenyl]methyl}-3-[(3,5-difluorophenyl)-<br>
(methyIsulfonyl)methylene]azetidine,<br>
l-((RS)-(4-chlorophenyl)[4-(diethylaminomethyl)-<br>
phenyl]methyl}-3-[(3,5-difluorophenyl)(methy1-<br>
sulfonyl)methylene]azetidine,<br>
l-((R)-(4-chlorophenyl)[4-(diethylaminomethyl)-<br>
phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl-<br>
sulfonyl)methylene]azetidine,<br>
l-((S)-(4-chlorophenyl)[4-(diethylaminomethyl)-<br>
phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl-<br>
sulfonyl)methylene]azetidine,<br>
l-{(RS)-(4-chlorophenyl)[4-(piperazin-2-one-4-<br>
ylmethyl)phenyl]methyl}-3-[(3, 5-difluorophenyl) (methy1-<br>
sulfonyDmethylene] azetidine,<br>
l-{ (R)-(4-chlorophenyl) [4-(piperazin-2-one-4-ylmethyl)-<br>
phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl-<br>
sulfonyl)methylene]azetidine,<br>
l-{ (S)-(4-chlorophenyl) [4-(piperazin-2-one-4-ylmethyl)-<br>
phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl-<br>
sulfonyl)methylene]azetidine,<br>
l-{(RS)-(4-chlorophenyl)[4-(imidazol-1-ylmethyl)-<br>
phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl-<br>
sulfonyl)methylene]azetidine,<br>
l-((R)-(4-chlorophenyl)[4-(imidazol-1-ylmethyl)-<br>
phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl-<br>
sulfonyl)methylene]azetidine,<br>
l-{ (S) - (4-chlorophen.yl) [4-(imidazol-1-ylmethyl)-<br>
phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl-<br>
sulfonyl)methylene]azetidine,<br>
(RS)-l-{(4-chlorophenyl)[4-(N,N-<br>
dimethylcarbamoyl)phenyl]methyl}-3-[(3,5-<br>
difluorophenyl)(methylsulfonyl)methylene]azetidine.<br><br>
1- [bis (4-chlorophenyl) methyl] -3- [ (3-hydroxyphenyl).-(methylsulfonyl)methylene]azetidine,<br>
1-[bis(4-chlorophenyl)methyl]-3-[(methylsulfonyl)(3-pyrrolidinylphenyl)methylene]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(3-hydroxy-methylphenyl) (methylsulfonyl)methylene]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-{(methylsulfonyl)[3-(N-piperidylcarbamoyl)phenyl]methylene}azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(methylsulfonyl)(3-trifluoromethylsulfanylphenyl)(methylsulfonyl)-methylene]azetidine,<br>
1-[bis(4-fluorophenyDmethyl]-3-[(3, 5-difluorophenyl)-(methylsulfonyl)methylene]azetidine,<br>
1-[bis(2-fluorophenyl)methyl]-3-[(3, 5-difluorophenyl)-(methylsulfonyl)methylene]azetidine,<br>
1-[bis(3-fluorophenyl)methyl]-3-[(3, 5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, (RS)-1-[(4-chlorophenyl)(thiazol-2-yl)methyl]-3-[(methylsulfonyl)(phenyl)methylene]azetidine, (R)-1-[(4-chlorophenyl)(thiazol-2-yl)methyl]-3-[(methylsulfonyl)(phenyl)methylene]azetidine, (S)-1-[(4-chlorophenyl)(thiazol-2-yl)methyl]-3-[(methylsulfonyl)(phenyl)methylene]azetidine, (RS)-1-[(4-chlorophenyl)(thien-2-yl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, (R)-1-[(4-chlorophenyl)(thien-2-yl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, (S)-l-[(4-chlorophenyl)(thien-2-yl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, l-benzhydryl-3-[(ethylsulfonyl)(phenyl)methylene]-azetidine,<br>
l-[bis(4-chlorophenyl)methyl]-3-{{3-[N-(4-methylpiperazinyl)carbamoyl]phenyl}(methylsulfonyl)-methylene}azetidine.<br><br>
1-[bis(4-chlorophenyl)methyl]-3-{[3- (2,2-dimethylcarbohydrazido)phenyl](methylsulfonyl)-methylene}azetidine,<br>
1-[bis(thien-2-yl)methyl]-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, 1-[bis(p-tolyl)methyl]-3-[(methylsulfonyl)-(phenyl)methylene]azetidine,<br>
1-[(4-chlorophenyl) (4-hydroxymethylphenyl)methyl] -3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-azetidine,<br>
1-[bis(4-chlorophenyl)methyl]-3-[(3-methylaminophenyl)-(methylsulfonyl)methylene]azetidine,<br>
(RS)-l-[(4-chlorophenyl)(thiazol-2-yl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, (R)-1-[(4-chlorophenyl)(thiazol-2-yl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, (S)-l-[(4-chlorophenyl)(thiazol-2-yl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(methylsulfonyl)(2-methoxycarbonylthien-5-yl)methylene]azetidine, (RS)-1-[bis(4-chlorophenyl)methyl]-3-hydroxy-3-[(methylsulfonyl)(2-methoxycarbonylthien-5-yl)methyl]azetidine,<br>
1-[bis(4-chlorophenyl)methyl]-3-[(2-isobutylamino-carbonylthien-5-yl)(methylsulfonyl)methylene]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(RS)-(3-methoxy-carbonylphenyl)(methylsulfonyl)methyl]azetidin-3-ol, 1-[bis(4-chlorophenyl)methyl]-3-[(RS)-(methyl¬sulfonyl) (pyridin-4-yl)methyl]azetidin-3-ol, 1-[bis(4-chlorophenyl)methyl]-3-[(RS)-(methylsulfonyl)(pyridin-3-yl)methyl]azetidin-3-ol, 3-((1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(3-(morpholin-4-yl)propyl)benzamide.<br><br>
3- ({1- [bis (4-chlvrophenyl) methyl] azetidin-3-<br>
ylidene}(methanesulfonyl)methyl)-N-(3-<br>
dimethylarainopropyl)benzamide,<br>
3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-<br>
ylidene}(methanesulfonyl)methyl)-N-(2-(pyrrolidin-1-<br>
yl)ethyl)benzamide,<br>
3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-<br>
ylidene}(methanesulfonyl)methyl)-N-(2-dimethylamino-l-<br>
methylethyl)benzamide,<br>
3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-<br>
ylidene}(methanesulfonyl)methyl)-N-(piperidin-1-<br>
yl)benzamide,<br>
3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-<br>
ylidene}(methanesulfonyl)methyl)-N-isobutylbenzamide,<br>
3-((1-[bis(4-chlorophenyl)methyl]azetidin-3-<br>
ylidene}(methanesulfonyl)methyl)-N-(3-(imidazol-1-<br>
yl)propyl)benzamide,<br>
3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-<br>
ylidene}(methanesulfonyl)methyl)-N-(2-<br>
dimethylaminoethyl)benzamide,<br>
N'-methylhydrazide of 3-((1-[bis(4-chlorophenyl)-<br>
methyl]azetidin-3-ylidene}(methanesulfonyl)-<br>
methyl)benzoic acid,<br>
3-((1-[bis(4-chlorophenyl)methyl]azetidin-3-<br>
ylidene}(methanesulfonyl)methyl)-N-(2-(morpholin-4-<br>
yl)ethyl)benzamide,<br>
3-((1-[bis(4-chlorophenyl)methyl]azetidin-3-<br>
ylidene} (methanesulfonyl) methyl)-N-(1-ethylpyrrolidin- •'<br>
2-ylmethyl)benzamide,<br>
3-((1-[bis(4-chlorophenyl)methyl]azetidin-3-<br>
ylidene}(methanesulfonyl)methyl)-N-(2,2-<br>
dimethylpropyl)benzamide,<br>
3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-<br>
ylidene}(methanesulfonyl)methyl)-N-<br>
(cyclohexylmethyl)benzamide.<br><br>
3-((1-[bis(4-chlorophenyl)methyl]azetidin-3-<br>
ylidene}(methanesulfonyl)methyl)-N-<br>
(cyclopropylmethyl)benzamide,<br>
3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-<br>
ylidene} (methanesulfonyl)methyl)-N-(2-<br>
methylbutyl)benzamide,<br>
3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-<br>
ylidene}(methanesulfonyl)methyl)-N-(2-<br>
phenylpropyl)benzamide,<br>
3-({1-[bis(4-chlorophenyI)methyl]azetidin-3-<br>
ylidene}(methanesulfonyl)methyl)-N-(tetrahydrofuran-2-<br>
ylmethyl)benzamide,<br>
3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-<br>
ylidene}(methanesulfonyl)methyl)-N-(2,2-<br>
diphenylethyl)benzamide,<br>
3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-<br>
ylidene}(methanesulfonyl)methyl)-N-(2-<br>
ethylbutyl)benzamide,<br>
methyl ester of 4-{[3-({1-[bis(4-chlorophenyl)methyl]-<br>
azetidin-3-ylidene}(methanesulfonyl)methyl)-<br>
benzoylamino]methyl}cyclohexanecarboxylic acid,<br>
2-amino-l-{4-[3-({l-[bis(4-chlorophenyl)methyl]-<br>
azetidin-3-ylidene}(methanesulfonyl)methyl)phenyl]-<br>
piperazin-l-yl}ethanone,<br>
tert-butyl ester of (2-{4-[3-({1-[bis(4-chlorophenyl)-<br>
methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-<br>
phenyl]piperazin-l-yl}-2-oxoethyl)carbamic acid,<br>
l-{4-[3-({l-[bis(4-chlorophenyl)methyl]azetidin-3-<br>
ylidene}(methanesulfonyl)methyl)phenyl]piperazin-1-yl}-<br>
2-(methylamino)ethanone,<br>
tert-butyl ester of (2-{4-[3-((1-[bis(4-<br>
chlorophenyl)methyl]azetidin-3-<br>
ylidene}(methanesulfonyl)methyl)phenyl]piperazin-1-yl }-<br>
2-oxoethyl)-N-methylcarbamic acid.<br><br>
N-methylamide of 4-[3-({1-[bis(4-chlorophenyl)-<br>
methyl] azetidin-3-yliciene} (methanesulfonyl) methyl) -<br>
phenyl]piperazine-1-carbothioic acid,<br>
N-methylamide of 4-[3-((1-[bis(4-chlorophenyl)methyl]-<br>
a2etidin-3-ylidene}(methanesulfonyl)methyl)phenyl]-<br>
piperazine-1-carboxylic acid,<br>
methyl ester of 4-[3-((1-[bis(4-chlorophenyl)methyl]-<br>
azetidin-3-ylidene}(methanesulfonyl)methyl)-<br>
phenyl]piperazine-l-carboxylic acid,<br>
l-[3-({l-[bis(4-chlorophenyl)methyl]azetidin-3-<br>
ylidene}(methanesulfonyl)methyl)phenyl]-4-<br>
isobutylpiperazine,<br>
l-[3-({l-[bis(4-chlorophenyl)methyl]azetidin-3-<br>
ylidene}(methanesulfonyl)methyl)phenyl]-4-<br>
ethylpiperazine,<br>
4-acetyl-1-[3-({1-[bis(4-chlorophenyl)methyl]azetidin-<br>
3-ylidene}(methanesulfonyl)methyl)phenyl]piperazine,<br>
l-{4-[3-({l-[bis(4-chlorophenyl)methyl]azetidin-3-<br>
ylidene}(methanesulfonyl)methyl)phenyl]piperazin-1-yl}-<br>
2-dimethylaminoethanone,<br>
1-[3-({1-[bis(4-chlorophenyl)methyl]a2etidin-3-<br>
ylidene)(methanesulfonyl)methyl)phenyl]piperazine,<br>
tert-butyl ester of 4-[3-((1-[bis(4-chlorophenyl)-<br>
methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-<br>
phenyl]piperazine-1-carboxylic acid,<br>
1-[bis(4-methoxycarbonylphenyl)methyl]-3-[(3,5-<br>
dif luorophenyl) (methylsulfonyl) methylene] azetidine',<br>
3-acetoxy-l-[bis(4-methoxycarbonylphenyl)methyl]-3-<br>
[(RS)-(3,5-difluorophenyl)(methylsulfonyl)methyl]-azetidine,<br>
(RS)-4-[4-((4-chlorophenyl){3-[(3,5-<br>
difluorophenyl)(methanesulfonyl)methylene]azetidin-1-yl}methyl)benzyl]morpholine,<br>
4-(4-{3-[(l-benzhydrylazetidin-3-ylidene)(methane¬sulfonyl )methyl]phenoxy}butyl)morpholine,<br><br>
4-(4-{3-[{l-benzhydiylazetidin-3-ylidene)(methane-sulfonyl)methyl]phenoxy}propyl)morpholine, N-(1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}thien-2-ylsulfonamide,<br>
N-{1-[bis (4-chlorophenyl)methyl]azetidin-3-yl}-4-methoxyphenylsulfonamide,<br>
N-[4-(N-(l-[bis{4-chlorophenyl)methyl]azetidin-3-yl}-sulfamoyl)phenyl]acetamide,<br>
N-(1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-4-metbyIphenylsulfonamide,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3,4-dimethoxyphenylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3-fluorophenylsulfonamide,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3,4-dichlorophenylsulfonamide,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3-cyanophenylsulfonamide,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-2,5-dimethoxyphenylsulfonamide,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3-trifluoromethylphenylsulfonamide,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}naphth-2-ylsulfonamide,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}naphth-1-ylsulfonamide,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3, 4-difluorophenylsulfonamide,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-1-methy1-IH-imidazol-4-ylsulfonamide, N-[4-(N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}sulfamoyl)-2-chlorophenyl]acetamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}pyrid-3-ylsulfonamide,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-4-fluorophenylsulfonamide,<br><br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}quinol-8-ylsulfonamide,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-ylIphenylsulfonamide,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}(phenylmethyl)sulfonamide,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3,5-difluorophenylsulfonamide,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}pyrid-2-ylsulfonamide,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-(3-fluoro-5-pyrrolidin-1-ylphenyl)sulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-methyl-4-fluorophenylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-methylquinol-8-ylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-methyIphenylsulfonamide,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-methyl(phenylmethyl)sulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3-sulfamoyIphenylsulfonamide,<br>
2-benzenesulfonyl-N-{l-[bis(4-chlorophenyl)methyl]-azetidin-3-yl}acetamide,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-2-(4-toluene-4-sulfonyl)acetamide, (3-chloro-4-(methylsulfonyl)thiophene-2-carboxy)-{1- [bis (4-chlorophenyl) methyl"] azetidin-3-yl] amide, N-{1-[bis (4-chlorophenyl)methyl]azetidin-3-yl}-3-(2-phenylethylenesulfonyl)propionamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-4-(methylsulfonyl)benzamide,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-4-(methanesulfonyl)benzamide, (5-(methylsulfonyl)thiophene-2-carboxy)-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}amide,<br><br>
(5-methylsulfonyl-3-methyl-4-vinylthiophene-<br>
2-carboxy) {1- [bis (4-chlorophenyl)inethvl] azetidin-<br>
3-yl}amide,<br>
(RS)-N-{1-[(4-chlorophenyl)(pyridin-3-yl)methyl]-<br>
azetidin-3-yl}-3,5-difluorobenzenesulfonamide,<br>
(RS)-N-(1-[(4-chlorophenyl)(pyrimidin-5-yl)methyl]-<br>
azetidin-3-yl}-3,5-difluorobenzenesulfonamide,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-<br>
N-(6-chloropyrid-2-yl)methylsulfonamide,<br>
N-(1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-<br>
N-(6-ethylpyrid-2-yl)methylsulfonamide,<br>
N-(1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-<br>
N-(quinol-6-yl)methylsulfonamide,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-<br>
N-(quinol-5-yl)methylsulfonamide,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-<br>
N-(isoquinol-5-yl)methylsulfonamide,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-<br>
N-(pyrid-3-yl)methylsulfonamide,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-<br>
N-(pyrid-1-oxide-3-yl)methylsulfonamide,<br>
N-(1R,2S,4S)-(bicyclo[2.2.1]hept-2-yl)-N-{1-[bis-<br>
(4-chlorophenyl)methyl]azetidin-3-yl}methylsulfonamide,<br>
N-(1R,2R,4S)-(bicyclo[2.2.1]hept-2-yl)-N-{1-[bis-<br>
(4-chlorophenyl)methyl]azetidin-3-yl}methylsulfonamide,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-<br>
N-(3,5-difluorophenyl)methylsulfonamide,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl }-<br>
N-(thiazol-2-yl)methylsulfonamide,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-<br>
N-(3-methoxyphenyl)methylsulfonamide,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-<br>
N-(3-hydroxyphenyl)methylsulfonamide,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-<br>
N-(3-(hydroxymethyl)phenyl)methylsulfonamide.<br><br>
ethyl N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-<br>
N-(methylsulfonyl)-3-aminobenzoate,<br>
N-(1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-<br>
N-(isobutylpiperid-4-yl)methylsulfonamide,<br>
N-benzyl-N-{1-[bis(4-chlorophenyl)methyl]azetidin-<br>
3-yl}amine,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-<br>
N-(3,5-difluorobenzyl)amine,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-<br>
N-(3,5-difluorobenzyl)methylsulfonamide,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-<br>
N-(pyrid-3-ylmethyl)methylsulfonamide,<br>
N-{1-[bis(4-fluorophenyl)methyl]azetidin-3-yl}-<br>
N-(3,5-difluorophenyl)methylsulfonamide,<br>
(RS)-N-{1-[(4-chlorophenyl)(pyrid-3-yl)methyl]azetidin-<br>
3-yl}-N-(3,5-difluorophenyl)methylsulfonamide,<br>
(R)-N-{1-[(4-chlorophenyl)(pyrid-3-yl)methyl]azetidin-<br>
3-yl}-N-(3,5-difluorophenyl)methylsulfonamide,<br>
(S)-N-{1-[(4-chlorophenyl)(pyrid-3-yl)methyl]azetidin-<br>
3-yl}-N-(3,5-difluorophenyl)methylsulfonamide,<br>
(RS)-N-{1-[(4-chlorophenyl)(pyrid-4-yl)methyl]azetidin-<br>
3-yl}-N-(3,5-difluorophenyDmethylsulfonamide,<br>
(R)-N-{1-[(4-chlorophenyl)(pyrid-4-yl)methyl]azetidin-<br>
3-yl}-N-(3,5-difluorophenyl)methylsulfonamide,<br>
(S)-N-{1-[(4-chlorophenyl)(pyrid-4-yl)methyl]azetidin-<br>
3-yl}-N-(3,5-difluorophenyDmethylsulfonamide,<br>
(RS)-N-{1-[(4-chlorophenyl)(pyrimidin-5-yl)methyl]-<br>
azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide, -<br>
(R)-N-(1-[(4-chlorophenyl)(pyrimidin-5-yl)methyl]-<br>
azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide,<br>
(S)-N-{1-[(4-chlorophenyl)(pyrimidin-5-yl)methyl]-<br>
azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide,<br>
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-<br>
difluorophenyl)benzylsulfonamide,<br>
their optical isomers and their pharmaceutically<br>
acceptable salts with an inorganic or organic acid.<br><br>
And even more particularly preferred are the following azetidine derivatives:<br>
l-[bis(4-chlorophenyl)methyl]-3-[(RS)-(3,5-difluoro-phenyl)(methylsulfonyl)methyl]azetidin-3-ol, 3-acetoxy-l-[bis(4-chlorophenyl)methyl]-3-[(RS)-(3,5-difluorophenyl)(methylulphonyl)methyl)methylsulfon ylmethyl]azetidine,<br>
1-[bis(4-chlorophenyl)methyl]-3-[(3, 5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, their optical isomers and their pharmaceutically acceptable salts with an inorganic or organic acid.<br>
Mention may be made, as examples of pharmaceutically acceptable salts of the azetidine derivatives, of the following salts: benzenesulfonate, hydrobromide, hydrochloride, citrate, ethanesulfonate, fumarate, gluconate, iodate, isethionate, maleate, methanesulfonate, methylenebis-p-oxynaphthoate, nitrate, oxalate, pamoate, phosphate, salicylate, succinate, sulfate, tartrate, theophyllinacetate and p-toluenesulfonate.<br>
Other CBl [lacuna] antagonists of use in the combinations according to the invention are, for example, the pyrazole derivatives disclosed in EP 576 357, EP 658 546, EP 656 354, WO 97/19063 and WO 00/46209, the benzothiophene and benzofuran derivatives disclosed in WO 96/02248 or the arylsulfonamides disclosed in WO 98/37061. Mention may in particular be made of the products known under the code SR141716 and LY320135.<br>
The synergistic effect of the combination of sibutramine and of a CBl [lacuna] antagonist on food intake was determined according to the following protocol:<br>
Obese Fa/fa Zucker rats aged 7 weeks and originating from Iffa-Credo, France, were used in this study. The rats are housed in individual cages and<br><br>
weighed every day between 8 and 10 o'clock in the morning. The amount of food is also weighed each morning at the same time. This food (M20, Pietrement, France) is changed every day and the rats have free access thereto for 24 hours. All the rats are treated for a week with the vehicle (miglyol 812N and 0.5% methylcellulose/0.2% polysorbate 80) in two consecutive administrations. The rats are treated from the 8th day with the vehicle, the CBl [lacuna] antagonist (1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine) or sibutramine by the oral route (see table below).<br>
The sibutramine is dissolved in a 0.5% methylcellulose/0.2% polysorbate 80 solution and administered at a dose of 3 mg/kg; the CBl [lacuna] antagonist is dissolved in miglyol 812N (Hiils, Germany) at a dose of 0.6 mg/kg and the two products are administered under a volume of 1 ml/kg. Each group is composed of 12 to 14 animals. The following groups are formed and the animals are treated for five days at the rate of two consecutive administrations every day.<br><br><br>
The food consumption of each animal is measured every day. The results are expressed as mean amount of food consumed during the 5 days of treatment. The results obtained are given in the table below.<br><br>
'p0.05   **p0.01  ***p0.0001<br>
The results show that, in the animals receiving the sibutramine and CBl [lacuna] antagonist combination, the reduction in food consumption is much greater has that of the animals treated either with sibutramine alone or with the CBl [lacuna] antagonist alone.<br>
The compounds of the combination can be • employed orally, parenterally, transdermally or rectally, either simultaneously or separately or spread out over time.<br>
The present invention also relates to the pharmaceutical compositions comprising the combination of sibutraminfe, its hydrate or one of its pharmaceutically acceptable salts and of a CBl receptor antagonist in the pure state or with one or more compatible and pharmacologically acceptable diluents and/or adjuvants and/or optionally in combination with another pharmaceutically compatible and physiologically<br><br>
active product for a use which is either simultaneous or separate or spread out over time.<br>
Use may be made, as solid compositions for oral administration, of tablets, pills, powders (hard gelatin capsules, cachets) or granules. In these compositions, the active principles are mixed with one or more inert diluents, such as starch, cellulose, sucrose, lactose or silica, under an argon stream. These compositions can also comprise substances other than the diluents, for example one or more lubricants such as magnesium stearate or talc, a colorant, a coating (dragees) or a glaze.<br>
Use may be made, as liquid compositions for oral administration, of pharmaceutically acceptable solutions, suspensions, emulsions, syrups and elixirs comprising inert diluents, such as water, ethanol, glycerol, vegetable oils or liquid paraffin. These compositions can comprise substances other than the diluents, for example wetting, sweetening, thickening, flavouring or stabilizing products.<br>
The sterile compositions for parenteral administration can preferably be solutions in aqueous or nonaqueous form, suspensions or emulsions. Use may be made, as solvent or vehicle, of water, propylene glycol, a polyethylene glycol, vegetable oils, in particular olive oil, injectable organic esters, for example ethyl oleate, or other suitable organic solvents. These compositions can also comprise adjuvants, in particular wetting, isotonizing, emulsifying, dispersing and stabilizing agents. Sterilization can be carried out in several ways, for example by aseptic filtration, by incorporating sterilizing agents in the composition, by irradiation or by heating. They can also be prepared in the form of sterile .solid compositions which can be dissolved at<br><br>
the time of use in sterile water or any other injectable sterile medium.<br>
The compositions for rectal administration are suppositories or rectal capsules which comprise, in addition to the active product, excipients such as cocoa butter, semisynthetic glycerides or polyethylene glycols.<br>
The pharmaceutical compositions generally comprise 0.5 to 10 mg of sibutramine and 0.1 to 200 mg of the CBl [lacuna] antagonist.<br>
The present invention also relates to the method for the treatment of obesity which consists in administering, to the patient, a combination according to the invention either simultaneously or separately or spread out over time.<br>
The doses depend on the desired effect, on the duration of treatment and on the administration route used; they are generally from 1 to 15 mg of sibutramine per day by the oral route for an adult and from 0.10 to 500 mg of the CBl [lacuna] antagonist per day by the oral route for an adult.<br>
Generally, the doctor will determine the appropriate dosage according to the age, weight and any other factor specific to the subject to be treated.<br><br><br>
CLAIMS<br>
1.	A combination of a CBl [lacuna]<br>
antagonist and of sibutramine, its hydrate or one of<br>
its pharmaceutically acceptable salts.<br>
2.	The combination as claimed in claim 1,<br>
for which the CBl [lacuna] antagonist is a compound of<br>
formula:<br><br>
R1 represents either an aromatic chosen from phenyl, naphthyl or indenyl, these aromatics being unsubstituted or substituted by one or more halogen, alkyl, alkoxy, -CO-alk, hydroxyl, -COOR5, formyl, trifluoromethyl, trifluoromethylsulfanyl, trifluoromethoxy, nitre, -NRSRT, -CO-NH-NReR?, -N(alk)COORa, cyano, -CONHR9, -CO-NRieRn, alkylsulfanyl, hydroxyalkyl, -0-alk-NRi2Ri3 or alkylthioalkyl, or a heteroaromatic chosen from the benzofuryl,<br><br>
benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl,<br>
2,3-dihydrobenzofuryl, 2,3-dihydrobenzothienyl,<br>
indolinyl, indolyl, isochromanyl, isoquinolyl, pyridyl,<br>
quinolyl, 1,2,3,4-tetrahydroisoquinolyl,<br>
1,2,3,4-tetrahydroquinolyl, thiazolyl or thienyl rings,<br>
it being possible for these heteroaromatics to be<br>
unsubstituted or substituted by a halogen, alkyl,<br>
alkoxy, -COOR5, trifluoromethyl,<br>
trifluoromethylsulfanyl, trifluoromethoxy, nitro,<br>
-NReRv, -CO-NH-NReRv, cyano, -CONHR9, alkylsulfanyl,<br>
hydroxyalkyl or alkylthioalkyl,<br>
R3 and R4,   which are identical or different, represent either an aromatic chosen from phenyl, naphthyl or indenyl, these aromatics being unsubstituted or substituted by one or more halogen, alkyl, alkoxy, formyl, hydroxy1, trifluoromethyl, trifluoromethoxy, -CO-alk, cyano, -COOR5, -CONRioRu/ -CO-NH-NRsR,, alkylsulfanyl, hydroxyalkyl, -alk-NRgRi or alkylthioalkyl, or a heteroaromatic chosen from the benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, 2,3-dihydrobenzofuryl, 2,3-dihydrobenzo¬thienyl, furyl, isochromanyl, isoquinolyl/ pyrrolyl, quinolyl, 1,2,3,4-tetrahydroisoquinolyl, thiazolyl or thienyl rings, it being possible for these heteroaromatics to be unsubstituted or substituted by a . halogen, alkyl, alkoxy, hydroxy 1, trif luoromethyl,' trifluoromethoxy, cyano, -COOR5, -CO-NH-NReR?, -CONRioRiir--alk-NRgRi, alkylsulfanyl, hydroxyalkyl or alkylthioalkyl,<br>
R5 is an alkyl radical or a phenyl radical optionally substituted by one or more halogen atoms.<br>
Re and R7, which are identical or different, represent a hydrogen atom or an alkyl, -COOalk, cycloalkyl,<br><br>
alkylcycloalkyl, -alk-0-alk or hydroxyalkyl radical or else Re  and R7 form, together with the nitrogen atom to which they are attached, a saturated or unsaturated and mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl, -COalk, -COOalk, -CO-NHalk, 'CS-NHalk, -CO-alk-NRi4Rj5, 0x0, hydroxyalkyl, -alk-0-alk or -CO-NH2 radicals,<br>
Re represents an alkyl radical,<br>
R9 represents a hydrogen atom or a radical of the type alkyl or alkyl substituted by dialkylamino, phenyl, cycloalkyl (optionally substituted by -COOalk} or a saturated or unsaturated and mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising one or more heteroatoms chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl radicals,<br>
R10 and R11 which are identical or different, represent a hydrogen atom or an alkyl radical or else R10 and R11 form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by an alkyl radical,<br>
R12 and R13, which are identical or different, represent a hydrogen atom or an alkyl or cycloalkyl radical or else R12 and R13 form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen.<br><br>
sulfur and nitrogen and optionally being substituted by an alkyl, -COalk, -COOalk, -CO-NHalk, -CS-NHalk or -CO-alk-NRnRis radical or a saturated mono- or bicyclic heterocycle having 3 to 10 ring members and comprising a heteroatom chosen from oxygen, sulfur and nitrogen,<br>
R14 and R15, which are identical or different, represent a hydrogen atom or an alkyl or -COOalk radical,<br>
R16 and R17 form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen,<br>
R' represents a hydrogen atom or a -CO-alk radical,<br>
or R represents a CHR18 radical and<br>
RIB represents an -NHCORig or -N (R20)-"-21 radical,<br>
Y is CO or S02,<br>
R4 and R3, which are identical or different, represent either an aromatic chosen from phenyl, naphthyl and indenyl, these aromatics being unsubstituted or substituted by one or more halogen, alkyl, alkoxy, formyl, hydroxy1, trifluoromethyl, trifluoromethoxy, -CO-alk, cyano, -COOH, -COOalk, -CONR22R23* -C0-NH-NR24R2S, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, hydroxyalkyl or -alk-NH22R23, or a heteroaromatic chosen from the benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chroma'nyl, 2,3-dihydrobenzofuryl, 2,3-dihydrobenzothienyl, pyrimidinyl, furyl, imidazolyl, isochromanyl.<br><br>
isoquinolyl, pyrrolyl, pyridyl, quinolyl, 1,2,3,4-tetrahydroisoquinolyl, thiazolyl and thienyl rings, it being possible for these heteroaromatics to be unsubstituted or substituted by a halogen, alkyl, alkoxy, hydroxy1, trifluoromethyl, trifluoromethoxy, cyano, -COOH, -COOalk, -CO-NH-NR24R25. -CONR22R23, -alk-NR24R35, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl or hydroxyalkyl,<br>
Ri9 represents an -alk-S02-R26 radical, an -alk-S02-CH=CH-R26 radical, a Heti radical substituted by -SO2-R26 or a phenyl radical substituted by -SO2-R26 or -alk-S02-R26,<br>
R20 represents a hydrogen atom or an alkyl radical,<br>
R21 represents a phenylalkyl, Heti or Ari radical,<br>
R22 and R23, which are identical or different represent a hydrogen atom or an alkyl radical or else R22 and R23 form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and _ nitrogen and optionally being substituted by one or more alkyl,<br>
R24 and R2S, which are identical or different, represent a hydrogen atom or an alkyl, -COOalk, cycloalkyl, alkylcycloalkyl, -alk-0-alk or hydroxyalkyl radical or else R24 and R25 form, together with the nitrogen atom to which they are attached, a saturated or unsaturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being<br><br>
substituted by one or more alkyl, -COalk, -COOalk, -CO-NHalk, -CS-NHalk, oxo, hydroxyalkyl, -alk-0-alk or -CO-NH2,<br>
R26 represents an alkyl, Ari or Heti radical,<br>
Ari represents a phenyl, naphthyl or indenyl radical, these radicals optionally being substituted by one or more halogen, alkyl, alkoxy, cyano, -CO-alk, -COOH, -COOalk, -CONR27R2B, -CO~NH-NR29R3o, alkylsulf anyl, alkylsulfinyl, alkylsulfonyl, -alk-NR29R30f -NRasRso alkylthioalkyl, formyl, hydroxyl, hydroxyalkyl, Het, -0-alk-NHcycloalkyl, OCF3, CF3, -NH-CO-alk, -SO2NH2, -NH-COCH3, -NH-COOalk or Het or else on 2 adjacent carbon atoms by dioxymethylene,<br>
Heti represents an unsaturated or saturated mono- br bicyclic heterocycle having 3 to 10 ring members and comprising one or more heteroatoms chosen from oxygen,' sulfur and nitrogen which is optionally substituted by one or more alkyl, alkoxy, vinyl, halogen, alkoxycarbonyl, 0x0, hydroxyl, OCF3 or CF3, the nitrogenous heterocycles optionally being in their N-oxidized form,<br>
Rz7 and R28, which are identical or different, represent a hydrogen atom or an alkyl radical or else R27 and R28 form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycl-e having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl radicals,<br>
R29 and R30, which are identical or different, represent a hydrogen atom or an alkyl, -COOalk, cycloalkyl.<br><br>
.Ikylcycloalkyl, -alk-O-alk or hydroxyalkyl radical or else R29 and R30 form, together with the nitrogen atom to which they are attached, a saturated or unsaturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl, -COalk, -COOalk, -CO-NHalk, -CS~NHalk, 0x0, hydroxyalkyl, -alk-0-al-k or -CO-NH2 radicals,<br>
or R represents CHR31 and<br>
R31 represents an -N(R32)R33, -N (R32}-CO-R33 or -N (R32)-SO2R34 radical,<br>
R4 and R3, which are identical or different, represent either an aromatic chosen from phenyl, naphthyl and indenyl, these aromatics being unsubstituted or substituted by one or more halogen, alkyl, alkoxy, formyl, hydroxy1, trifluoromethyl, trifluoromethoxy, -CO-alk, cyano, -COOH, COOalk, -CONR22R23, -CO-NH-NR24R25, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, hydroxyalkyl or -alk-NR7R8, or a heteroaromatic chosen from the benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, . 2,3-dihydrobenzofuryl, 2,3-dihydrobenzothienyl, furyl, imidazolyl, isochromanyl, isoquinblyl, pyrrolyl, pyridyl, pyrimidyl, quinolyl, 1,2,3,4-tetra-hydroisoquinolyl, thiazolyl and thienyl rings, it being possible for these heteroaromatics to be unsubstituted or substituted by a halogen, alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, -COOH, -COOalk, -CO-NH-NR24R25, -CONR22R23, -alk-NR24R25, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl,<br><br>
alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl or hydroxyalkyl,<br>
R32 represents a -C (R35) (R36)-Het2, -Hets, -C (R35) (R35)-2' Arz, cycloalkyl or norbornyl radical,<br>
R33 represents a hydrogen atom or a hydroxyalkyl, -alk-COOalk, -alk-CONR22R23, -alk-NR22R23, alkoxy, Ar2, Hets, -CH2Ar2, -CH2Het2 or alkyl radical, the latter optionally substituted by one or more halogen,<br>
R34 represents a hydroxyalkyl, -alk-COOalk, -alk-CONR22R23, -alk-NR22R23- alkoxy, Ari, Het2, -CH2Ar2, -CH2Het2 or alkyl radical, the latter optionally substituted by one or more halogen,<br>
R35 represents a hydrogen atom or a hydroxyalkyl, -alk-COOalk, -alk-CONR22R23, -alk-NR22R23, alkoxyalkyl, Ar2, Het2, -CH2Ar2, -CH2Het2 or alkyl radical, the latter optionally substituted by one or more halogen,<br>
R36 represents a hydrogen atom or a hydroxyalkyl, -alk-COOalk, -alk-CONR22R23/ -alk-NRz2R23, alkoxyalkyl or alkyl radical, the latter optionally substituted by one or more halogen,<br>
or else R25  and R36 form, together with the carbon atom to which they are attached, a saturated mono- or bicyclic ring having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl,<br>
Ar2 represents a phenyl, naphthyl or indenyl radical, these various radicals optionally being substituted by one or more halogen, alkyl, alkoxy, -CO-alk, cyano,<br><br>
-COOH, -COOalk, -CONRBTRJS, -CO-NH-RsgRo, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, -alk-NRagRo/ -NR39R40/ alkylthioalkyl, formyl, CF3, OCF3, Het, -0-alk-NH-. cycLoalkyl, SO2NH2, hydroxyl, hydroxyalkyl, -NHCOalk or NHCOOalk or on 2 adjacent carbon atoms by dioxymethylene,<br>
Het2 represents an unsaturated or saturated mono- or bicyclic heterocycle having 3 to 10 ring members and comprising one or more heteroatoms chosen from oxygen, sulfur and nitrogen which is optionally substituted by one or more alkyl, alkoxy, halogen, alkoxycarbonyl, 0x0 or hydroxyl, the nitrogenous heterocycles optionally being in their N-oxidized form,<br>
R37 and R33, which are identical or different, represent a hydrogen atom or an alkyl radical or else Ri  and Rg form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl,<br>
R39 and R40/ which are identical or different, represent a hydrogen atom or an alkyl radical or else R39 and R40 form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl,<br>
alk represents an alkyl or alkylene radical,<br>
N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)benzyl sulpho namide, their optical isomers and their pharmaceutically acceptable salts.<br>
4.	The combination as claimed in claim 2, for which the compound of formula (I)<br>
is compounds:<br><br>
5.	The combination as claimed in claim 1, in which the CBl receptor antagonist is N-<br>
(piperidin-1 -yl)-5-(4-chlorophenyl)-1 (2,4-dichlorophenyl)-4-mehtyl-1 H-pyrazole-3-<br>
carboximide hydrochloride, its hydrates and its pharmaceutically acceptable salts or<br>
4-{6-methoxy-2-(4-mehtoxy-phenyl)-benzofuran-3-carbonyl}-benzonitrile<br>
and its pharmaceutically acceptable salts.<br>
6.	A pharmaceutical composition comprising a CBl receptor antagonist and<br>
sibutramine as claimed in any of claims 1 to 5 and pharmacologically acceptable<br>
diluents and/or adjuvants and/or optionally in combination with another<br>
pharmaceutically compatible and physiologically active product.<br>
7.	The pharmaceutical composition as claimed in claim 6 comprising 0.5 to lOmg<br>
of sibutramine and 0.1 to 200 mg of the CBl receptor antagonist.<br><br><br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NTg5LWNoZW5wLTIwMDMgYWJzdHJhY3QgZHVwbGljYXRlLnBkZg==" target="_blank" style="word-wrap:break-word;">589-chenp-2003 abstract duplicate.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NTg5LWNoZW5wLTIwMDMgYWJzdHJhY3QucGRm" target="_blank" style="word-wrap:break-word;">589-chenp-2003 abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NTg5LWNoZW5wLTIwMDMgY2xhaW1zIGR1cGxpY2F0ZS5wZGY=" target="_blank" style="word-wrap:break-word;">589-chenp-2003 claims duplicate.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NTg5LWNoZW5wLTIwMDMgY2xhaW1zLnBkZg==" target="_blank" style="word-wrap:break-word;">589-chenp-2003 claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NTg5LWNoZW5wLTIwMDMgY29ycmVzcG9uZGVuY2Ugb3RoZXJzLnBkZg==" target="_blank" style="word-wrap:break-word;">589-chenp-2003 correspondence others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NTg5LWNoZW5wLTIwMDMgY29ycmVzcG9uZGVuY2UgcG8ucGRm" target="_blank" style="word-wrap:break-word;">589-chenp-2003 correspondence po.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NTg5LWNoZW5wLTIwMDMgZGVzY3JpcHRpb24gKGNvbXBsZXRlKSBkdXBsaWNhdGUucGRm" target="_blank" style="word-wrap:break-word;">589-chenp-2003 description (complete) duplicate.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NTg5LWNoZW5wLTIwMDMgZGVzY3JpcHRpb24gKGNvbXBsZXRlKS5wZGY=" target="_blank" style="word-wrap:break-word;">589-chenp-2003 description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NTg5LWNoZW5wLTIwMDMgZm9ybS0xLnBkZg==" target="_blank" style="word-wrap:break-word;">589-chenp-2003 form-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NTg5LWNoZW5wLTIwMDMgZm9ybS0xOC5wZGY=" target="_blank" style="word-wrap:break-word;">589-chenp-2003 form-18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NTg5LWNoZW5wLTIwMDMgZm9ybS0yNi5wZGY=" target="_blank" style="word-wrap:break-word;">589-chenp-2003 form-26.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NTg5LWNoZW5wLTIwMDMgZm9ybS0zLnBkZg==" target="_blank" style="word-wrap:break-word;">589-chenp-2003 form-3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NTg5LWNoZW5wLTIwMDMgZm9ybS01LnBkZg==" target="_blank" style="word-wrap:break-word;">589-chenp-2003 form-5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NTg5LWNoZW5wLTIwMDMgb3RoZXJzLnBkZg==" target="_blank" style="word-wrap:break-word;">589-chenp-2003 others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NTg5LWNoZW5wLTIwMDMgcGN0IHNlYXJjaCByZXBvcnQucGRm" target="_blank" style="word-wrap:break-word;">589-chenp-2003 pct search report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NTg5LWNoZW5wLTIwMDMgcGN0LnBkZg==" target="_blank" style="word-wrap:break-word;">589-chenp-2003 pct.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NTg5LWNoZW5wLTIwMDMgcGV0aXRpb24ucGRm" target="_blank" style="word-wrap:break-word;">589-chenp-2003 petition.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="223153-an-inkjet-printhead.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="223155-a-process-for-the-distillative-separation-of-pentene-nitrile-isomers.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>223154</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>589/CHENP/2003</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>47/2008</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>21-Nov-2008</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>05-Sep-2008</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>21-Apr-2003</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>AVENTIS PHARMA S.A.</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>20 AVENUE RAYMOND ARON, F-92160 ANTONY,</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>PIOT-GROSJEAN, ODILE</td>
											<td>12 RUE GUY MOQUEST, F-94600 CHOISY LE ROI,</td>
										</tr>
										<tr>
											<td>2</td>
											<td>PICAUT, PHILIPPE</td>
											<td>81 RUE BOUCICAUT, F-92260 FONTENAY AUX ROSES,</td>
										</tr>
										<tr>
											<td>3</td>
											<td>PETITET, FRANCOIS</td>
											<td>9 RUE GRANDJEAN, F-94000 CRETEIL,</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A61K31/397</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/FR01/03022</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2001-10-01</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>00/12646</td>
									<td>2000-10-04</td>
								    <td>France</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/223154-combination-of-sibutramine-with-cannabinoid-1-receptor-antagonist by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 06:40:46 GMT -->
</html>
